The Board of Directors of Wockhardt Limited, at its meeting held on May 4, 2026, approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. For the quarter ended March 31, 2026, the company reported standalone revenue from operations of Rs. 516 Crores, a significant increase from Rs. 430 Crores in the previous quarter (Dec 2025) and Rs. 355 Crores in the corresponding quarter of the previous year (March 2025). This represents a 20% increase Quarter-on-Quarter (QoQ) and a 45.35% increase Year-on-Year (YoY). Standalone net profit for the quarter stood at Rs. 167 Crores, compared to Rs. 28 Crores in the previous quarter and Rs. 40 Crores in the same quarter last year. The board also approved a proposal for raising funds through various equity or convertible securities.

Wockhardt Limited is a global pharmaceutical and biotechnology organization headquartered in Mumbai, India. The company is exclusively engaged in the pharmaceutical business segment. It operates a diverse portfolio that includes manufacturing and marketing of pharmaceutical formulations, biopharmaceuticals, and active pharmaceutical ingredients (APIs). Wockhardt has a significant international presence with subsidiaries across the UK, USA, Ireland, and other global markets. Recently, the company reached a settlement agreement with Dr. Reddy’s Laboratories effective March 31, 2026, regarding a legal dispute over a Business Transfer Agreement, resulting in a net gain of Rs. 35 Crores. Additionally, the group decided to exit the US generic pharmaceutical business, leading to the voluntary liquidation of certain US subsidiaries in July 2025.